Apalutamide in Metastatic Hormone Sensitive Prostate cancerANOTHER Latest news for prostate cancer from the ASCO 2019 conference concluded few days ago:
In the TITAN trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression–free survival were significantly longer with the addition of apalutamide.
Apalutamide ALSO would probably be approved for metastatic hormone sensitive (castrate sensitive) prostate cancer by the year end in my predictions, YET AGAIN increasing the number of targetted therapies and chemotherapy in the already crowded treatment armamentarium of advanced prostate cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1903307
Dr Rajeentheran Suntheralingam
7th June 2019
Source:
Apalutamide in Metastatic Hormone Sensitive Prostate cancer
